Program
Ramucirumab
Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 533 open or running | phase 3since Jun 20, 2008 | Aug 13, 2007 | May 2027phase 2 · NCT05999994 |
| Arog Pharmaceuticals | 10 open or running | phase 1since Jun 14, 2017 | Jun 14, 2017 | none ahead |
| AstraZeneca | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | Feb 23, 2029phase 2 · NCT06996782 |
| Innovent Biologics | 10 open or running | phase 3since Dec 3, 2020 | Dec 3, 2020 | none ahead |
| Merck | 11 open or running | phase 2since May 31, 2024 | May 31, 2024 | May 9, 2028phase 2 · NCT06445972 |
| Sino Biopharmaceutical | 10 open or running | phase 1since Mar 24, 2023 | Mar 24, 2023 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Aug 13, 2007.
- Sep 25, 2015Phase 1 study in NeoplasmsEli Lilly · NCT02564198 · 29 enrolled · United States
- Mar 14, 2016Phase 2 study in Biliary Tract NeoplasmsEli Lilly · NCT02711553 · 309 enrolled · United States, Argentina, Australia and more
- May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more
- Jul 11, 2016Phase 2 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02831491
- Sep 8, 2016Phase 3 study in Gastroesophageal Junction AdenocarcinomaEli Lilly · NCT02898077 · 440 enrolled · China, Malaysia, Philippines and more
- Jun 14, 2017Arog Pharmaceuticals's first study: phase 1 study in Esophagogastric AdenocarcinomaNew to Arog PharmaceuticalsArog Pharmaceuticals · NCT03193918 · 30 enrolled · United States
- Oct 29, 20192 phase 2 studiesEli Lilly · NCT04145700, NCT04145349
- Jul 30, 2020Phase 1 study in HealthyEli Lilly · NCT04495478 · 50 enrolled · United States
- Sep 16, 2020Phase 1 study in Advanced Solid TumorEli Lilly · NCT04557384 · 3 enrolled · United States, Japan
- Dec 3, 2020Innovent Biologics's first study: phase 3 study in Gastric AdenocarcinomaNew to Innovent BiologicsInnovent Biologics · NCT04675983 · 36 enrolled · China
- Mar 24, 2023Sino Biopharmaceutical's first study: phase 1 study in Stomach NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05800418 · 88 enrolled · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- May 31, 2024Merck's first study: phase 2 study in Esophageal NeoplasmsNew to MerckMerck · NCT06445972 · 210 planned · United States, Brazil, Chile and more
- May 5, 2025AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT06996782 · 152 planned · United States, Belgium, Brazil and more
Ahead
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
- May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsMerck · NCT06445972
- Feb 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06996782
TargetBeta
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 58 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more | 2 | Recruiting | AstraZeneca | Feb 23, 2029 | 152 |
| NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Merck | May 9, 2028 | 210 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05800418Stomach Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Feb 18, 2020 | 88 |
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Innovent Biologics | Feb 12, 2023 | 36 |
| NCT04557384Advanced Solid Tumor · United States, Japan | 1 | Terminated | Eli Lilly | May 25, 2021 | 3 |
| NCT04495478Healthy · United States | 1 | Completed | Eli Lilly | May 9, 2021 | 50 |
| NCT04145700Sarcoma, Synovial · United States, Australia, Belgium and more | 2 | Terminated | Eli Lilly | Feb 23, 2023 | 23 |
| NCT04145349Desmoplastic Small Round Cell Tumor · United States, Australia, Germany and more | 2 | Completed | Eli Lilly | Jun 14, 2024 | 30 |
| NCT03193918Esophagogastric Adenocarcinoma · United States | 1 | Completed | Arog Pharmaceuticals | Jul 15, 2020 | 30 |
| NCT02898077Gastroesophageal Junction Adenocarcinoma · China, Malaysia, Philippines and more | 3 | Completed | Eli Lilly | Jun 30, 2020 | 440 |
| NCT02831491Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Eli Lilly | Jul 2017 | 0 |
| NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more | 1 | Completed | Eli Lilly | Oct 19, 2017 | 29 |
| NCT02711553Biliary Tract Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Eli Lilly | Feb 16, 2018 | 309 |
| NCT02564198Neoplasms · United States | 1 | Completed | Eli Lilly | Jul 16, 2019 | 29 |
| NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan | 2 | Completed | Eli Lilly | Oct 25, 2017 | 191 |
| NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Oct 27, 2017 | 245 |
| NCT02443883Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Eli Lilly | Nov 18, 2016 | 164 |
| NCT02443324Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 1 | Completed | Eli Lilly | Aug 31, 2018 | 175 |
| NCT02435433Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Mar 15, 2018 | 399 |
| NCT02426125Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Eli Lilly | Apr 21, 2017 | 530 |
| NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 3 | Active, not recruiting | Eli Lilly | Jan 23, 2019 | 545 |
| NCT02314117Metastatic Gastric Adenocarcinoma · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Jan 17, 2017 | 645 |
| NCT02082210Liver Neoplasms · United States | 2 | Completed | Eli Lilly | Dec 5, 2017 | 97 |
| NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain | 1 | Completed | Eli Lilly | May 2, 2018 | 142 |
| NCT02069041Carcinoma, Hepatocellular · Taiwan | 1 | Completed | Eli Lilly | Sep 2016 | 8 |
| NCT01983878Stomach Neoplasms · Japan | 2 | Completed | Eli Lilly | Jan 2015 | 36 |
| NCT01703091Non-small Cell Lung Cancer Metastatic · Japan | 2 | Completed | Eli Lilly | Dec 2014 | 197 |
| NCT01682135Solid Tumor · China | 1 | Completed | Eli Lilly | Mar 2015 | 28 |
| NCT01634555Solid Tumors · United States | 2 | Completed | Eli Lilly | Aug 2013 | 29 |
| NCT01567163Malignant Solid Tumor · United States | 2 | Completed | Eli Lilly | Dec 2012 | 22 |
| NCT01515306Malignant Solid Tumor · United States | 2 | Completed | Eli Lilly | Mar 20, 2013 | 48 |
| NCT01427933Breast Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2013 | 141 |
| NCT01286818Colorectal Neoplasms · Japan | 1 | Completed | Eli Lilly | Feb 2012 | 6 |
| NCT01282463Urethral Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Feb 2015 | 148 |
| NCT01256567Breast Neoplasms · Japan | 1 | Completed | Eli Lilly | Nov 2012 | 7 |
| NCT01253525Adenocarcinoma · Japan | 1 | Completed | Eli Lilly | Oct 2011 | 6 |
| NCT01246960Stomach Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2013 | 168 |
| NCT01234402Breast Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Oct 2013 | 153 |
| NCT01183780Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 17, 2014 | 1,072 |
| NCT01170663Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 2013 | 665 |
| NCT01168973Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Dec 2013 | 1,253 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01140347Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Mar 2014 | 565 |
| NCT01111604Colonic Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Dec 2013 | 158 |
| NCT01017731Neoplasms · United States | 2 | Completed | Eli Lilly | Apr 2010 | 68 |
| NCT01005355Advanced Solid Tumors · Japan | 1 | Completed | Eli Lilly | Feb 2011 | 15 |
| NCT00917384Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 2012 | 355 |
| NCT00862784Colorectal Neoplasms · Canada, Spain | 2 | Completed | Eli Lilly | Apr 2011 | 48 |
| NCT00793975Neoplasms · United States | 1 | Completed | Eli Lilly | Jun 2009 | 37 |
| NCT00786383Neoplasms · United States | 1 | Completed | Eli Lilly | Jan 2009 | 25 |
| NCT00735696Carcinoma, Non-Small-Cell Lung · United States, United Kingdom | 2 | Completed | Eli Lilly | Oct 2011 | 41 |
| NCT00721162Ovarian Neoplasms · United States, United Kingdom | 2 | Completed | Eli Lilly | May 2012 | 60 |
| NCT00703326Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Eli Lilly | Mar 31, 2013 | 1,144 |
| NCT00683475Prostatic Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2011 | 138 |
| NCT00627042Carcinoma, Hepatocellular · United States | 2 | Completed | Eli Lilly | May 2011 | 42 |
| NCT00533702Melanoma · United States | 2 | Completed | Eli Lilly | May 2011 | 106 |
| NCT00515697Carcinoma, Renal Cell · United States | 2 | Completed | Eli Lilly | May 2011 | 39 |
How it is read
Names in the registry
- “Ramucirumab”, 36 entries
- “IMC-1121B (ramucirumab)”, 4 entries
- “Ramucirumab (IMC-1121B)”, 4 entries
- “IMC-1121B”, 4 entries
- “ramucirumab (IMC-1121B)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Stomach Neoplasms, 7 studies
- Neoplasms, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Breast Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.